Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774081 · ClinicalTrials.gov registry record
Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study
A clinical trial of Insulin Sensitivity, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT04774081 is a study of Insulin Sensitivity that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 13 participants, below the 72-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04774081, a study of Insulin Sensitivity, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp
Conditions Studied
Interventions
- DEVICE 24h Continuous glucose monitoring and urinary C-peptide collection
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2022-02-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04774081
The ClinicalTrials.gov registry entry for NCT04774081 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (82% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 1 intervention - of which 24h Continuous glucose monitoring and urinary C-peptide collection is the first listed.
NCT04774081 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT04774081 about?
NCT04774081 is a clinical study titled "Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study". This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp
What is the current status of trial NCT04774081?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2021-02-08. Estimated completion is 2022-02-21.
What conditions does trial NCT04774081 study?
This clinical trial studies the following conditions: Insulin Sensitivity.
What interventions are being tested in trial NCT04774081?
The interventions under investigation include: 24h Continuous glucose monitoring and urinary C-peptide collection (DEVICE).
Who is sponsoring clinical trial NCT04774081?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04774081 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Sensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Countermeasures to Circadian Misalignment
RECRUITING · NA
-
Effect of Pulsatile Hormone Administration on Insulin Action
RECRUITING · NA
-
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.